Coegin Pharma (NGM:COEGIN) Research & Development: kr0.00 Mil (TTM As of Mar. 2026)


NGM:COEGIN Coegin Pharma NGM:COEGIN
29 GF Score
Price kr3.62
! 2 Warning Signs
View Full Analysis

What is Coegin Pharma Research & Development?

Coegin Pharma NGM:COEGIN +3.72% 29 Research & Development is kr0.00 Mil as of Mar. 2026. GuruFocus rates NGM:COEGIN with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Coegin Pharma's Research & Development for the three months ended in Mar. 2026 was kr0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00 Mil.

Coegin Pharma  (NGM:COEGIN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Coegin Pharma Research & Development Related Terms

Coegin Pharma Research & Development Historical Data

* Premium members only.

The historical data trend for Coegin Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coegin Pharma Research & Development Chart

Coegin Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Coegin Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NGM:COEGIN
29GF Score
Coegin Pharma NGM:COEGIN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coegin Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr0.00 Mil mean?
Coegin Pharma (NGM:COEGIN) has a Research & Development of kr0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Coegin Pharma and its competitors.
Is Coegin Pharma's Research & Development too high?
Coegin Pharma's current Research & Development is kr0.00 Mil. Overall, Coegin Pharma has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Coegin Pharma's Research & Development compare to VRTX and REGN?
Coegin Pharma's Research & Development of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Coegin Pharma and its competitors. Coegin Pharma's current Research & Development is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coegin Pharma stock overvalued right now?
Coegin Pharma (NGM:COEGIN) has a current Research & Development of kr0.00 Mil. The current Research & Development is kr0.00 Mil. Coegin Pharma's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Coegin Pharma (NGM:COEGIN), the current Research & Development is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Coegin Pharma Business Description

Other Exchanges 7Z6:Germany
Address c/o Medicon Village, Lund, SWE, 223 81
Coegin Pharma AB is a Swedish biotechnology company with projects in hair growth, skin pigmentation, heart attacks, and leukemia. Its project portfolio builds on three distinct, patented technology platforms: the FOL peptide technology, the pigmentation peptide technology, and the cPLA2 alpha technology. The company's project portfolio consists of both cosmetic dermatology and drug development projects. Currently, it is focused on the cosmetic dermatology projects, which include the NPP-4 project for skin pigmentation and the Follicopeptide project for hair growth. In addition, the company's project portfolio also includes three drug development projects: FOL026, for the treatment of myocardial infarction (heart attack); AVX420 for the treatment of leukemia; and AVX001.
29GF Score

Get the complete analysis for NGM:COEGIN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.62
Price